Home › NDC Lookup › RxCUI directory › RxCUI 199422

Nevirapine 200 MG Oral Tablet — RxCUI 199422

RxNorm drug concept · Semantic clinical drug
RxCUI 199422 Semantic clinical drug · SCD ● Current RxNorm concept 6 FDA products 11 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI199422
Official nameNevirapine 200 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped6
Package NDCs mapped11
Reported Medicaid activity (SDUD)83 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Nevirapine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Nevirapine is an antiviral drug that belongs to a class called NNRTIs — it works by blocking a key enzyme HIV needs to copy itself. But HIV is clever: if you only take one drug, th...
  • What exactly is nevirapine and why do I need to take it with other HIV medicines?
  • That first 14-day period at a once-daily lower dose is called the lead-in period, and it's actually really important — it's been shown to significantly reduce the chance of develop...
  • Why do I have to start at a lower dose for the first two weeks?
📖 Read our full Nevirapine guide →

🕸️ Concept Web — How Nevirapine 200 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Nevirapine 200 MG Oral Tablet RxCUI 199422

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Nevirapine 53654
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Viramune 224890
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Nevirapine Oral Tablet 373046
    • Nevirapine Oral Product 1158093
    • Nevirapine Pill 1158094
    • Nevirapine Oral Tablet [Viramune] 367746
    • Viramune Oral Product 1186808
    • Viramune Pill 1186809
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Nevirapine 200 MG 316334
    • Nevirapine 200 MG Oral Tablet [Viramune] 211327
    • Nevirapine 200 MG [Viramune] 571769

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Nevirapine 200 MG SCDC · 316334
  • Nevirapine Oral Tablet SCDF · 373046
  • Nevirapine Oral Product SCDG · 1158093
  • Nevirapine Pill SCDG · 1158094

Brand-Name Concepts

  • Nevirapine 200 MG Oral Tablet [Viramune] SBD · 211327
  • Nevirapine 200 MG [Viramune] SBDC · 571769
  • Nevirapine Oral Tablet [Viramune] SBDF · 367746
  • Viramune Oral Product SBDG · 1186808
  • Viramune Pill SBDG · 1186809
  • Viramune BN · 224890

📦 FDA Products & Package NDCs

6 products · 11 package NDCs
11 package NDCs map to RxCUI 199422 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00378-4050-91 60 TABLET in 1 BOTTLE, PLASTIC (0378-4050-91) Nevirapine Mylan Pharmaceuticals Inc. 2012-05-22
31722-0505-01 100 TABLET in 1 BOTTLE (31722-505-01) Nevirapine Camber Pharmaceuticals, Inc. 2012-05-23
31722-0505-05 500 TABLET in 1 BOTTLE (31722-505-05) Nevirapine Camber Pharmaceuticals, Inc. 2012-05-23
31722-0505-10 1000 TABLET in 1 BOTTLE (31722-505-10) Nevirapine Camber Pharmaceuticals, Inc. 2012-05-23
31722-0505-60 60 TABLET in 1 BOTTLE (31722-505-60) Nevirapine Camber Pharmaceuticals, Inc. 2012-05-23
33342-0004-09 60 TABLET in 1 BOTTLE (33342-004-09) Nevirapine Macleods Pharmaceuticals Limited 2019-01-28
42571-0131-29 6 BLISTER PACK in 1 CARTON (42571-131-29) / 10 TABLET in 1... NEVIRAPINE Micro Labs Limited 2012-05-22
42571-0131-60 60 TABLET in 1 BOTTLE (42571-131-60) NEVIRAPINE Micro Labs Limited 2012-05-22
65162-0209-06 60 TABLET in 1 BOTTLE (65162-209-06) Nevirapine Amneal Pharmaceuticals LLC 2014-04-30
65862-0027-10 6 BLISTER PACK in 1 CARTON (65862-027-10) / 10 TABLET in 1... Nevirapine Aurobindo Pharma Limited 2012-05-22
65862-0027-60 60 TABLET in 1 BOTTLE (65862-027-60) Nevirapine Aurobindo Pharma Limited 2012-05-22
Observed labelers: Camber Pharmaceuticals, Inc. (4) · Aurobindo Pharma Limited (2) · Micro Labs Limited (2) · Amneal Pharmaceuticals LLC (1) · Macleods Pharmaceuticals Limited (1) · Mylan Pharmaceuticals Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$0.1528
Range $0.1528–$0.1528 · middle 50% $0.1528–$0.1528 · 3 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.